Drugs / Evexomostat
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02743637 | Feb 2016 → Dec 2019 | cancer, metastatic neoplasm | SynDevRx, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05455619 | Aug 2022 → Dec 2026 expected | hormone receptor-positive breast cancer | SynDevRx, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05570253 | Oct 2022 → Oct 2027 expected | triple-negative breast carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | SynDevRx, Inc. | Results SynDevRx to Present AMELIA™-1 Data at ASCO 2026 Showing Improved PI3K/AKT Class Inhibitor Responses in Breast Cancer syndevrx.com ↗
Evexomostat combination shows clinical benefit and favorable safety in heavily pretreated HR+/HER2− mBC patients with PI3K pathway alterations. |
| 2026-02-20 | SynDevRx, Inc. | Results SynDevRx Publishes Data On Evexomostat, Establishes New Metabo-Oncology Treatment Modality syndevrx.com ↗
SynDevRx today announced the publication of a seminal research article in Frontiers in Oncology detailing the anti-tumor and systemic metabolic improvements of its lead investigational therapy, evexomostat in pre-clinical models of obesity-accelerated cancer. |
| 2025-12-02 | SynDevRx, Inc. | Results Aretha-1 Initial Efficacy and Safety Data in mTNBC Patients To Be Presented at SABCS syndevrx.com ↗
Safety Run-in Cohort Results Show Anti-tumor Activity Plus Systemic Metabolic Improvements with Evexomostat Plus Eribulin in Late-line Metastatic TNBC Patients to be Presented at SABCS 2025 |
| 2024-03-26 | SynDevRx, Inc. | Results AACR Journal MCT Publishes Initial Disclosure Article on Evexomostat/SDX-7320 syndevrx.com ↗
This report describes the physicochemical and pharmacological characterization of SDX-7320 (evexomostat), a polymer-drug conjugate of the novel MetAP2 inhibitor (MetAP2i) SDX-7539. |
| 2023-09-19 | SynDevRx, Inc. | Results Amelia-1 Clinical Trial Fully Open To Recruitment, 1st Patient Data on Combination Study with PI3K Inhibitor and SERD syndevrx.com ↗
Evexomostat, a novel MetAP2 inhibitor, controlled PI3K-induced hyperglycemia in the first study patient, consistent with pre-clinical data. |
| 2023-04-14 | SynDevRx, Inc. | Results New Experimental Treatment for Prostate Cancer Revealed at AACR syndevrx.com ↗
Evexomostat (SDX-7320) shows potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant. |
| 2022-09-03 | SynDevRx, Inc. | Results Aug. 31, 2022 – SynDevRx Presents Scientific Poster on Anti-Fibrosis Data with Evexomostat at the 2022 IPF Conference in Boston syndevrx.com ↗
Evexomostat significantly improved lung function following lung injury, reduced fibrotic foci, and reduced lung edema both alone and even more potently when combined with nintedanib. |
| 2020-11-16 | SynDevRx, Inc. | Results SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients syndevrx.com ↗
SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients |
| 2020-10-21 | SynDevRx, Inc. | Results SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show syndevrx.com ↗ |
| 2019-03-04 | SynDevRx, Inc. | Results SDX at AACR: Obesity confers immuno-suppressive tumor microenvironment – Poster Presentation syndevrx.com ↗
A novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor SDX-7320 inhibits the growth of EO771 mammary gland tumors and ameliorates the immunosuppressive tumor immune micro-environment (TIME) |
All press releases naming this drug 17 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evexomostat | “A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast...” NCT05570253 ↗ |
| Known as | Metap2 inhibitor sdx-7320 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802217 ↗ |
| Known as | SDX-7320 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02743637 ↗ |
| Action | Inhibit | “novel MetAP2 inhibitor” NCT02743637 ↗ |
| Modality | Other / unclassified | “synthetic copolymer-drug conjugate” NCT02743637 ↗ |
| Route | Subcutaneous | “subcutaneously administered SDX-7320” NCT02743637 ↗ |
| Target | METAP2 | “a novel MetAP2 inhibitor” NCT05455619 ↗ |